Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Abstract HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metas...

Full description

Bibliographic Details
Main Authors: Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Experimental Hematology & Oncology
Subjects:
HER2
Trastuzumab
Pertuzumab
T-DM1
Bispecific antibody
Ertumaxomab
Online Access:http://link.springer.com/article/10.1186/s40164-017-0091-4

Internet

http://link.springer.com/article/10.1186/s40164-017-0091-4

Similar Items